Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we ...
Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE at its earnings and acquisition.
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
Pfizer has reached a turning point.
Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s latest stock calls as he discussed the bullish AI investment thesis amid the ...
Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.
Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.
The company incurred a loss in its most recent quarterly results.
Shares of Pfizer Inc. PFE rallied 1.65% to $27.05 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.33% to 6,740.02 and Dow ...
Zacks.com on MSN
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results